- Merck & Co‘s 2025 adjusted EPS (Earnings Per Share) forecast is set between $8.88 and $9.03, falling short of the estimated $9.19.
- The company forecasts sales ranging from $64.1 billion to $65.6 billion, lower than the expected $67.37 billion.
- Merck & Co maintains its outlook for an adjusted gross margin of about 82.5%, which surpasses the estimate of 81%.
- For the fourth quarter, the adjusted EPS reached $1.72, a significant increase compared to the same period last year, and above the estimated $1.63.
- Sales for the fourth quarter were $15.62 billion, reflecting a 6.8% year-over-year growth, and exceeding the estimated $15.45 billion.
- Merck & Co announced halting shipments of Gardasil to China starting in February 2025, continuing through at least mid-year.
Merck & Co on Smartkarma
Analyst coverage on Merck & Co by Smartkarma showcases positive sentiments from top independent analysts. Baptista Research‘s report highlights Merck & Co‘s robust operational performance and strategic advances, especially in its oncology portfolio driven by KEYTRUDA. The company’s 4% revenue growth, strong global uptake of KEYTRUDA, and successful product launches contribute to its positive trajectory. Baptista Research also aims to provide an independent valuation of the company using a Discounted Cash Flow methodology.
Business Breakdowns discusses Merck & Co as a pharmaceutical leader focusing on innovation in oncology and future drug pipeline development. Key insights include the significant revenue generated by Keytruda, Merck’s history of breakthrough innovations, and the company’s commitment to research and development. The report underlines Merck & Co‘s strategic approach to navigating challenges in the pharmaceutical industry, positioning it for continued success.
A look at Merck & Co Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 4 | |
| Growth | 4 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Merck & Co., Inc. is a global health care company that covers various sectors including pharmaceuticals, animal health, and consumer care. Assessing the company’s long-term outlook based on Smartkarma Smart Scores, it reflects a positive trend with strong scores in Dividend and Growth aspects, indicating a stable dividend and potential for future growth. The company’s resilience score also signifies a certain level of robustness in managing challenges, while the momentum score suggests a steady pace of development. However, the lower value score may point to the company being relatively overvalued compared to its industry peers.
In conclusion, Merck & Co.’s overall outlook appears favorable for the long term, especially in terms of dividends and growth prospects. Despite some concerns regarding valuation, the company’s diversified portfolio and global presence position it well for sustained success in the ever-evolving health care industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
